PCSA

Processa Pharmaceuticals (PCSA)

About Processa Pharmaceuticals (PCSA)

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Details

Daily high

$1.27

Daily low

$1.20

Price at open

$1.25

52 Week High

$18.00

52 Week Low

$1.19

Market cap

4.1M

Dividend yield

0.00%

Volume

31,798

Avg. volume

148,565

P/E ratio

-.23

Processa Pharmaceuticals News